SCHEMBL4516377

SCHEMBL4516377

CCOc1ccccc1-n1c(CCl)nc2sccc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 10/20 0.53
ALDH1A1 P00352 3/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 2/20 0.45
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
APLNR P35414 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CACNA2D1 P54289 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4400208 0.84 HIF1A (0.71) HIF1AALDH1A1L3MBTL1LMNAPKM
SCHEMBL1703503 0.82 ALDH1A1 (0.70) ALDH1A1CYP2D6CYP2C19L3MBTL1LMNA
SCHEMBL4526805 0.82 HIF1A (0.76) HIF1AALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL4517443 0.81 HIF1A (0.65) HIF1AALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL4527044 0.80 HIF1A (0.72) HIF1AALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL14473822 0.79 HIF1A (0.57) HIF1AALDH1A1L3MBTL1LMNAPKM
SCHEMBL4515459 0.79 HIF1A (0.77) HIF1AALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL9734824 0.78 ALDH1A1 (0.75) ALDH1A1CYP2D6CYP2C19L3MBTL1LMNA
SCHEMBL4465299 0.74 L3MBTL1 (0.79) HIF1AALDH1A1L3MBTL1LMNAPKM
SCHEMBL14303441 0.72 HIF1A (0.68) HIF1AALDH1A1L3MBTL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170834-A1 Fused Pyrimidones and Thiopyrimidones, and Uses Thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090170834-A1 Fused Pyrimidones and Thiopyrimidones, and Uses Thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090170834-A1 Fused Pyrimidones and Thiopyrimidones, and Uses Thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
WO-2007076085-A2 FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF PROLEXYS PHARMACEUTICALS, INC . (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170834-A1 Fused Pyrimidones and Thiopyrimidones, and Uses Thereof TYMP, TYMS, MKI67 HIF1A 3569/4885ALDH1A1 596/4885CYP2D6 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.